Ann: Phase IIb Dog Trial Achieves Interim Clinical Endpoints, page-124

And a very good morning to you to NZT

I agree with what you said. But.

Elanco hold the composition of matter patents until 2022 or 23/2024.

Needless to say that everybody here would be getting fed up with the time lines being dragged out, the patent thing is the only reason I can think of. i.e PAA hold the patents to use MPL on the mTOR pathways until at least 2033 but Elanco own MPL now, their patents start to run out 2022.

All the testing that has/is being done is all positive and encouraging and has been done at minimal cost to PAA. Every thing seems to be pointing to next year to me, there could be better places to be if you are interested in trading.

And the best of luck to you as well